Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum

T. Nakahara, Toshihide Kuroki, E. Ohta, T. Kajihata, H. Yamada, M. Yamanaka, K. Hashimoto, T. Tsutsumi, M. Hirano, H. Uchimura

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.

Original languageEnglish
Pages (from-to)213-219
Number of pages7
JournalParkinsonism and Related Disorders
Volume9
Issue number4
DOIs
Publication statusPublished - Mar 1 2003

Fingerprint

Methamphetamine
Corpus Striatum
Substantia Nigra
Haloperidol
Gene Expression
Messenger RNA
vpr Genes
Dopaminergic Neurons
Parkinsonian Disorders
Reverse Transcription
Parkinson Disease
Dopamine
Polymerase Chain Reaction
Mutation
Brain
Pharmaceutical Preparations
Genes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum. / Nakahara, T.; Kuroki, Toshihide; Ohta, E.; Kajihata, T.; Yamada, H.; Yamanaka, M.; Hashimoto, K.; Tsutsumi, T.; Hirano, M.; Uchimura, H.

In: Parkinsonism and Related Disorders, Vol. 9, No. 4, 01.03.2003, p. 213-219.

Research output: Contribution to journalArticle

Nakahara, T, Kuroki, T, Ohta, E, Kajihata, T, Yamada, H, Yamanaka, M, Hashimoto, K, Tsutsumi, T, Hirano, M & Uchimura, H 2003, 'Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum', Parkinsonism and Related Disorders, vol. 9, no. 4, pp. 213-219. https://doi.org/10.1016/S1353-8020(02)00052-4
Nakahara, T. ; Kuroki, Toshihide ; Ohta, E. ; Kajihata, T. ; Yamada, H. ; Yamanaka, M. ; Hashimoto, K. ; Tsutsumi, T. ; Hirano, M. ; Uchimura, H. / Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum. In: Parkinsonism and Related Disorders. 2003 ; Vol. 9, No. 4. pp. 213-219.
@article{b2a8ac9216654c7e87412416403fa6cf,
title = "Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum",
abstract = "We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.",
author = "T. Nakahara and Toshihide Kuroki and E. Ohta and T. Kajihata and H. Yamada and M. Yamanaka and K. Hashimoto and T. Tsutsumi and M. Hirano and H. Uchimura",
year = "2003",
month = "3",
day = "1",
doi = "10.1016/S1353-8020(02)00052-4",
language = "English",
volume = "9",
pages = "213--219",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum

AU - Nakahara, T.

AU - Kuroki, Toshihide

AU - Ohta, E.

AU - Kajihata, T.

AU - Yamada, H.

AU - Yamanaka, M.

AU - Hashimoto, K.

AU - Tsutsumi, T.

AU - Hirano, M.

AU - Uchimura, H.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.

AB - We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.

UR - http://www.scopus.com/inward/record.url?scp=0037334558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037334558&partnerID=8YFLogxK

U2 - 10.1016/S1353-8020(02)00052-4

DO - 10.1016/S1353-8020(02)00052-4

M3 - Article

C2 - 12618056

AN - SCOPUS:0037334558

VL - 9

SP - 213

EP - 219

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 4

ER -